Ashfield rolls in cloud service to speed up market launch

By Dani Bancroft contact

- Last updated on GMT

Ashfield rolls in cloud service to speed up market launch

Related tags: Health care, Health care provider

UDG’s Ashfield division will use Salesforce Health Cloud to help outsource clients launch therapies into EU and US markets through “seamless” data exchange.

Ashfield Commercial & Medical Services is the larger division​ of UDG Healthcare plc, providing commercialisation services for the 8,000 person contract research organisation (CRO).

By implementing Salesforce Health Cloud platform, the firm hopes to increase communication between health care providers their care teams, improving patient compliance and data integrity.

The implementation comes in response to FDA issued guidelines requiring purpose-built data management systems​ to better protect patient data.

Lucy MacLauchlan, a spokesperson for Ashfield, told us, “We will be migrating existing programmes over to the new platform and it will be part of our integrated service offering for all programmes moving forward.”

MacLauchlan said the other key ways in which the new Health Cloud will help the biotech and pharma industry is with global patient compliance, operational efficiency, standardisation and set-up time, and to “speed up launch into new markets”.

One example of Ashfield’s clients is Diurnal Ltd., a Cardiff-based biopharma developing therapies for chronic endocrine disorders. Diurnal recently signed a deal​ with Ashfield to help commercialize its lead product – Infacort.

The Health Cloud platform will provide the capability to collect, store and analyse real-world data in a more seamless way – supporting the value proposition with payers and prescribers,” ​MacLauchlan added.

Patient support programmes

The cloud-based tool will also be used by Ashfield’s clients for patient support programmes, by creating tailored patient care plans and centralising all patient information for clinical trials in one place.

Our patient support programmes focus on adherence, persistence, education and support following treatment initiation in the real world,” ​MacLauchlan explained.

The platform can also provide access and additional data for Healthcare providers and patients. However, this would need to be determined on a programme basis, taking into account local regulations, and the requirements of [each party] in that therapy area.”

(Feature Image: Creative Commons CC0 1.0)

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Related suppliers

Follow us

Products

View more

Webinars